YSIOS CAPITAL

NorthSea Therapeutics Completes US$80 Million Series C Fundraising to Advance Clinical Programs in Metabolic Disorders

Retrieved on: 
Friday, December 17, 2021
Other Professional Services, Biotechnology, Pharmaceutical, Finance, Health, Hospitals, Professional Services, Clinical Trials, NASH, Icosabutate, NorthSea Therapeutics, Ysios Capital, Forbion, NASH, ICOSABUTATE, NORTHSEA THERAPEUTICS, YSIOS CAPITAL, FORBION

NorthSea Therapeutics B.V., (NST) a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, today announces the close of a USD 80 million Series C financing round.

Key Points: 
  • NorthSea Therapeutics B.V., (NST) a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, today announces the close of a USD 80 million Series C financing round.
  • Interim results showed a rapid and significant reduction of biomarkers in liver injury, inflammation, and fibrosis in biopsy-confirmed NASH patients.
  • In addition, treatment with Icosabutate showed a favorable safety and tolerability profile and additional improvements in atherogenic lipids and glycemic control.
  • NorthSea Therapeutics B.V.(NST) is a Dutch biotech company focused on developing structurally engineered fatty acids (SEFAs) for the treatment of NASH and other metabolic disorders.

Ysios Capital Closes its Third Fund at €216 Million ($260 Million)

Retrieved on: 
Wednesday, May 26, 2021
Science, Biotechnology, Research, Pharmaceutical, Finance, Health, Medical devices, Professional services, Economy, Articles, Finance, European Investment Fund, European Investment Bank, Venture capital, Microfinance, Ysios Capital, the European Investment Fund (EIF) & the European Guarantee Fund (EGF), YSIOS CAPITAL, THE EUROPEAN INVESTMENT FUND (EIF) & THE EUROPEAN GUARANTEE FUND (EGF)

Ysios Capital, Spains largest and leading European venture capital firm specialised in the biotechnology sector, announces today that it has closed its third fund, Ysios BioFund 3 (YBF 3) at 216 million ($260 million).

Key Points: 
  • Ysios Capital, Spains largest and leading European venture capital firm specialised in the biotechnology sector, announces today that it has closed its third fund, Ysios BioFund 3 (YBF 3) at 216 million ($260 million).
  • Karen Wagner, Managing Partner at Ysios Capital, added: We are very proud of the work Ysios has supported over the last decade.
  • Following an initial investment of 30 million, the European Investment Fund (EIF), part of the European Investment Bank Group and a leading player in the European Venture Capital market, mobilised an additional 30 million of participation in the fund.
  • The EIF designs and develops both venture and growth capital, guarantees and microfinance instruments that specifically target this market segment.